US6764697B1
(en)
|
1991-06-27 |
2004-07-20 |
Alza Corporation |
System for delaying drug delivery up to seven hours
|
US5160742A
(en)
*
|
1991-12-31 |
1992-11-03 |
Abbott Laboratories |
System for delivering an active substance for sustained release
|
IT1260505B
(it)
*
|
1992-06-01 |
1996-04-09 |
Poli Ind Chimica Spa |
Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
|
WO1995016451A1
(fr)
*
|
1992-06-22 |
1995-06-22 |
Franck Arno Gouchet |
Comprimes a liberation controlee de 4-asa
|
FR2692484B1
(fr)
*
|
1992-06-22 |
1995-06-30 |
Gouchet Franck |
Nouvelle forme galenique de 4-asa a liberation controlee.
|
AU670958B2
(en)
*
|
1992-08-05 |
1996-08-08 |
Mayne Pharma International Pty Ltd |
Pelletised pharmaceutical composition
|
NZ253999A
(en)
*
|
1992-08-05 |
1996-07-26 |
Faulding F H & Co Ltd |
Pelletised substained release medicament
|
US5914132A
(en)
*
|
1993-02-26 |
1999-06-22 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
IT1265092B1
(it)
*
|
1993-05-31 |
1996-10-30 |
Giuliani Spa |
Preparato per uso come integratore alimentare, o dietetico,a rilascio mirato nel colon
|
DE4332394A1
(de)
*
|
1993-09-23 |
1995-03-30 |
Falk Pharma Gmbh |
Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
|
US5536505A
(en)
*
|
1993-12-15 |
1996-07-16 |
Eastman Chemical Company |
Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends
|
US5523095A
(en)
*
|
1993-12-15 |
1996-06-04 |
Eastman Chemical Company |
Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
|
AU689250B2
(en)
|
1994-04-22 |
1998-03-26 |
Astellas Pharma Inc. |
Colon-specific drug release system
|
AT403988B
(de)
*
|
1994-05-18 |
1998-07-27 |
Lannacher Heilmittel |
Festes orales retardpräparat
|
US5686106A
(en)
*
|
1995-05-17 |
1997-11-11 |
The Procter & Gamble Company |
Pharmaceutical dosage form for colonic delivery
|
HU228856B1
(en)
*
|
1995-12-21 |
2013-06-28 |
Ferring Farma Lab |
Modified release oral pharmaceutical composition containing 5-asa for the treatment of bowel diseases
|
US5840332A
(en)
*
|
1996-01-18 |
1998-11-24 |
Perio Products Ltd. |
Gastrointestinal drug delivery system
|
US6245351B1
(en)
|
1996-03-07 |
2001-06-12 |
Takeda Chemical Industries, Ltd. |
Controlled-release composition
|
US8071128B2
(en)
|
1996-06-14 |
2011-12-06 |
Kyowa Hakko Kirin Co., Ltd. |
Intrabuccally rapidly disintegrating tablet and a production method of the tablets
|
AUPO247496A0
(en)
|
1996-09-23 |
1996-10-17 |
Resmed Limited |
Assisted ventilation to match patient respiratory need
|
WO1998026767A2
(en)
*
|
1996-12-17 |
1998-06-25 |
Poli Industria Chimica S.P.A. |
Site-specific controlled release dosage formulation for mesalamine
|
WO1998027967A1
(en)
*
|
1996-12-20 |
1998-07-02 |
Dumex-Alpharma A/S |
Release-controlled coated tablets
|
US5891474A
(en)
*
|
1997-01-29 |
1999-04-06 |
Poli Industria Chimica, S.P.A. |
Time-specific controlled release dosage formulations and method of preparing same
|
US5788987A
(en)
*
|
1997-01-29 |
1998-08-04 |
Poli Industria Chimica Spa |
Methods for treating early morning pathologies
|
DE19732903A1
(de)
|
1997-07-30 |
1999-02-04 |
Falk Pharma Gmbh |
Pellet-Formulierung zur Behandlung des Intestinaltraktes
|
IL134591A0
(en)
*
|
1997-09-25 |
2001-04-30 |
Bayer Ag |
Medicament formulation with a controlled release of an active agent
|
US6974590B2
(en)
*
|
1998-03-27 |
2005-12-13 |
Cima Labs Inc. |
Sublingual buccal effervescent
|
US20030091629A1
(en)
*
|
1998-03-27 |
2003-05-15 |
Cima Labs Inc. |
Sublingual buccal effervescent
|
US20030118645A1
(en)
*
|
1998-04-29 |
2003-06-26 |
Pather S. Indiran |
Pharmaceutical compositions for rectal and vaginal administration
|
CA2360655C
(en)
|
1999-01-29 |
2007-03-20 |
Losan Pharma Gmbh |
Pharmaceutical compositions
|
US6723342B1
(en)
|
1999-02-08 |
2004-04-20 |
Fmc Corporation |
Edible coating composition
|
US6432448B1
(en)
|
1999-02-08 |
2002-08-13 |
Fmc Corporation |
Edible coating composition
|
ATE251449T1
(de)
|
1999-06-14 |
2003-10-15 |
Cosmo Spa |
Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
|
US8895064B2
(en)
|
1999-06-14 |
2014-11-25 |
Cosmo Technologies Limited |
Controlled release and taste masking oral pharmaceutical composition
|
US6500462B1
(en)
|
1999-10-29 |
2002-12-31 |
Fmc Corporation |
Edible MCC/PGA coating composition
|
US7897140B2
(en)
*
|
1999-12-23 |
2011-03-01 |
Health Research, Inc. |
Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
|
US6451345B1
(en)
|
2000-01-20 |
2002-09-17 |
Eurand Pharmaceuticals Ltd. |
Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
|
US6627223B2
(en)
*
|
2000-02-11 |
2003-09-30 |
Eurand Pharmaceuticals Ltd. |
Timed pulsatile drug delivery systems
|
IT1318625B1
(it)
|
2000-07-14 |
2003-08-27 |
Roberto Valducci |
Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
|
CA2421240C
(en)
|
2000-09-06 |
2010-03-23 |
Mitsubishi Pharma Corporation |
Granular preparations for oral administration
|
CA2359812C
(en)
|
2000-11-20 |
2004-02-10 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
|
TR200300731T2
(tr)
|
2000-11-28 |
2004-08-23 |
Fmc Corporation |
Yenebilir PGA kaplama bileşimi
|
IL157634A0
(en)
|
2001-03-13 |
2004-03-28 |
Penwest Pharmaceuticals Co |
Chronotherapeutic dosage forms containing glucocorticosteroid
|
KR20010069756A
(ko)
*
|
2001-05-08 |
2001-07-25 |
유형선 |
소염진통제인 아세메타신을 함유하며 장관내 특히대장에서의 약물 방출 속도가 조절되는 약물 전달 체계에대한 약제학적 경구용 조성물 및 그에 대한 제조방법
|
US20030068356A1
(en)
*
|
2001-07-10 |
2003-04-10 |
Pather S. Indiran |
Sequential drug delivery systems
|
US6500454B1
(en)
*
|
2001-10-04 |
2002-12-31 |
Eurand Pharmaceuticals Ltd. |
Timed, sustained release systems for propranolol
|
US9358214B2
(en)
*
|
2001-10-04 |
2016-06-07 |
Adare Pharmaceuticals, Inc. |
Timed, sustained release systems for propranolol
|
AR036797A1
(es)
|
2001-10-15 |
2004-10-06 |
Ferring Bv |
Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn
|
WO2003032916A2
(en)
*
|
2001-10-16 |
2003-04-24 |
Structural Bioinformatics Inc. |
Organosulfur inhibitors of tyrosine phosphatases
|
HU231030B1
(hu)
*
|
2001-11-23 |
2019-12-30 |
Warner Chilcott Company, Llc |
Többszörös bevonattal ellátott gyógyszer dózisforma
|
MXPA04006163A
(es)
*
|
2001-12-20 |
2004-11-01 |
Pharmacia Corp |
Formas de dosis de liberacion sostenida del orden-cero y metodo de fabricacion de las mismas.
|
US8829198B2
(en)
*
|
2007-10-31 |
2014-09-09 |
Proteotech Inc |
Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
|
AU2003248747A1
(en)
|
2002-06-27 |
2004-01-19 |
Health Research, Inc. |
Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
|
WO2004005289A2
(en)
*
|
2002-07-02 |
2004-01-15 |
Health Research, Inc. |
Efficient synthesis of pyropheophorbide a and its derivatives
|
GB0217056D0
(en)
*
|
2002-07-23 |
2002-08-28 |
Ass Octel |
Use
|
US7799752B2
(en)
|
2002-08-14 |
2010-09-21 |
Quest International Services B.V. |
Compositions comprising encapsulated material
|
EP1393706A1
(en)
*
|
2002-08-14 |
2004-03-03 |
Quest International B.V. |
Fragranced compositions comprising encapsulated material
|
JP2006507298A
(ja)
*
|
2002-10-30 |
2006-03-02 |
ファルマシア コーポレーション |
経口持続放出型錠剤、ならびにその製造法および使用法
|
US8367111B2
(en)
|
2002-12-31 |
2013-02-05 |
Aptalis Pharmatech, Inc. |
Extended release dosage forms of propranolol hydrochloride
|
TWI355276B
(en)
*
|
2003-01-14 |
2012-01-01 |
Akira Tsuji |
Gastrointestinal absorption enhancer mediated by p
|
JP2006521300A
(ja)
*
|
2003-03-31 |
2006-09-21 |
プリヴァ−ラケマ,エー.エス. |
活性物質として白金錯体を含有する医薬組成物およびその製造方法
|
CA2520197A1
(en)
|
2003-04-23 |
2004-11-04 |
Ferring B.V. |
Sachet for a pharmaceutical composition
|
WO2004099162A1
(en)
*
|
2003-04-30 |
2004-11-18 |
Ricerca Biosciences, Llc. |
Polycyclic diazodioxide-based bcl-2 protein antagonist
|
US20040242886A1
(en)
*
|
2003-04-30 |
2004-12-02 |
Sandeep Gupta |
Monocyclic diazodioxide based Bcl-2 protein antagonists related applications
|
CN102584813B
(zh)
*
|
2003-05-14 |
2016-07-06 |
Ngc药物公司 |
化合物及其在调节淀粉样蛋白β中的用途
|
US8916598B2
(en)
|
2003-05-30 |
2014-12-23 |
Proteotech Inc |
Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
|
US20100331380A1
(en)
*
|
2009-06-29 |
2010-12-30 |
Esposito Luke A |
Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
|
CA2529984C
(en)
|
2003-06-26 |
2012-09-25 |
Isa Odidi |
Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
|
US7057100B2
(en)
*
|
2003-06-26 |
2006-06-06 |
The J.C. Robinson Seed Co. |
Inbred corn line W23129
|
US7825106B2
(en)
|
2003-09-03 |
2010-11-02 |
Agi Therapeutics Ltd. |
Modified release formulations and methods of treating inflammatory bowel disease
|
US7737133B2
(en)
|
2003-09-03 |
2010-06-15 |
Agi Therapeutics Ltd. |
Formulations and methods of treating inflammatory bowel disease
|
KR100782918B1
(ko)
|
2003-09-19 |
2007-12-07 |
펜웨스트 파머슈티칼즈 컴파니 |
지연 방출성 제형
|
JP5610663B2
(ja)
|
2003-11-04 |
2014-10-22 |
スパーナス ファーマシューティカルズ インコーポレイテッド |
トロスピウムの1日1回剤形
|
US8709476B2
(en)
|
2003-11-04 |
2014-04-29 |
Supernus Pharmaceuticals, Inc. |
Compositions of quaternary ammonium compounds containing bioavailability enhancers
|
EP1547601A1
(en)
|
2003-12-23 |
2005-06-29 |
Ferring B.V. |
Coating method
|
WO2005065317A2
(en)
*
|
2003-12-31 |
2005-07-21 |
Cima Labs Inc. |
Effervescent oral fentanyl dosage form
|
CA2549642C
(en)
*
|
2003-12-31 |
2012-10-30 |
Cima Labs Inc. |
Effervescent oral opiate dosage forms and methods of administering opiates
|
NZ548216A
(en)
*
|
2003-12-31 |
2010-02-26 |
Cima Labs Inc |
Generally linear effervescent oral fentanyl dosage form and methods of administering
|
US7670624B2
(en)
|
2004-01-29 |
2010-03-02 |
Astella Pharma Inc. |
Gastrointestinal-specific multiple drug release system
|
WO2005090370A1
(en)
*
|
2004-02-05 |
2005-09-29 |
The Regents Of The University Of California |
Pharmacologically active agents containing esterified phosphonates and methods for use thereof
|
JP2005272347A
(ja)
*
|
2004-03-24 |
2005-10-06 |
Ohara Yakuhin Kogyo Kk |
固形製剤の製造方法
|
JP2007538103A
(ja)
|
2004-05-20 |
2007-12-27 |
ザ スクリップス リサーチ インスティテュート |
トランスサイレチン安定化
|
EP1768668A2
(en)
|
2004-06-16 |
2007-04-04 |
Tap Pharmaceutical Products, Inc. |
Multiple ppi dosage form
|
US20060135773A1
(en)
*
|
2004-06-17 |
2006-06-22 |
Semple Joseph E |
Trisubstituted nitrogen modulators of tyrosine phosphatases
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
JP2008505916A
(ja)
*
|
2004-07-09 |
2008-02-28 |
メタバシス・セラピューティクス・インコーポレイテッド |
チロシンホスファターゼの酸素/窒素複素環阻害剤
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
WO2006028970A1
(en)
|
2004-09-02 |
2006-03-16 |
Cengent Therapeutics, Inc. |
Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
|
US8747895B2
(en)
|
2004-09-13 |
2014-06-10 |
Aptalis Pharmatech, Inc. |
Orally disintegrating tablets of atomoxetine
|
ES2376108T3
(es)
|
2004-09-17 |
2012-03-09 |
Whitehead Institute For Biomedical Research |
Compuestos, composiciones y método para inhibir la toxicidad de la a-sinucleina.
|
US20060067889A1
(en)
*
|
2004-09-27 |
2006-03-30 |
Light Sciences Corporation |
Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents
|
US9884014B2
(en)
|
2004-10-12 |
2018-02-06 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions
|
NZ709754A
(en)
|
2004-10-21 |
2017-02-24 |
Adare Pharmaceuticals Inc |
Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
|
US20060105038A1
(en)
*
|
2004-11-12 |
2006-05-18 |
Eurand Pharmaceuticals Limited |
Taste-masked pharmaceutical compositions prepared by coacervation
|
US9149439B2
(en)
|
2005-03-21 |
2015-10-06 |
Sandoz Ag |
Multi-particulate, modified-release composition
|
US20090156545A1
(en)
*
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
JP5242375B2
(ja)
|
2005-04-01 |
2013-07-24 |
ザ レゲントス オブ ザ ユニバーシティ オブ カリフォルニア |
ホスホノ−ペント−2−エン−1−イルヌクレオシド及び類似体
|
US9161918B2
(en)
|
2005-05-02 |
2015-10-20 |
Adare Pharmaceuticals, Inc. |
Timed, pulsatile release systems
|
WO2007002109A2
(en)
*
|
2005-06-20 |
2007-01-04 |
The Regents Of The University Of California |
Multidentate pyrone-derived chelators for medicinal imaging and chelation
|
US8492428B2
(en)
*
|
2005-09-20 |
2013-07-23 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
WO2007076160A2
(en)
*
|
2005-12-28 |
2007-07-05 |
Acidophil Llc |
C-10 carbamates of taxanes
|
AU2007225088B2
(en)
|
2006-03-13 |
2012-09-13 |
Kyorin Pharmaceutical Co., Ltd |
Aminoquinolones as GSK-3 inhibitors
|
CN101460161A
(zh)
*
|
2006-03-29 |
2009-06-17 |
弗尔德里克斯制药股份有限公司 |
α-突触核蛋白毒性的抑制
|
JP5457830B2
(ja)
|
2006-04-03 |
2014-04-02 |
オディディ,イサ |
オルガノゾル被膜を含む制御放出送達デバイス
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
MY149863A
(en)
|
2006-08-03 |
2013-10-31 |
Nitec Pharma Ag |
Delayed-release glucocorticoid treatment of rheumatoid disease
|
JP5209625B2
(ja)
|
2006-08-28 |
2013-06-12 |
協和発酵キリン株式会社 |
アンタゴニストのヒトlight特異的ヒトモノクローナル抗体
|
RU2420268C2
(ru)
*
|
2006-09-04 |
2011-06-10 |
Панацея Биотек Лимитед |
Способ программируемой плавучей доставки
|
NZ575907A
(en)
|
2006-09-21 |
2011-03-31 |
Kyorin Seiyaku Kk |
5-substituted benzoxazines
|
JP2010507585A
(ja)
|
2006-10-19 |
2010-03-11 |
オースペックス・ファーマシューティカルズ・インコーポレイテッド |
置換インドール
|
US20100137421A1
(en)
*
|
2006-11-08 |
2010-06-03 |
Emmanuel Theodorakis |
Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
|
AU2007333667A1
(en)
|
2006-12-19 |
2008-06-26 |
Auspex Pharmaceuticals, Inc. |
Preperation and utility of CCR5 inhibitors
|
WO2008079371A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Encysive Pharmaceuticals, Inc. |
Modulators of c3a receptor and methods of use thereof
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
BRPI0808089A2
(pt)
|
2007-02-28 |
2014-07-15 |
Conatus Pharmaceuticals Inc |
Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c.
|
US20080234257A1
(en)
|
2007-03-15 |
2008-09-25 |
Auspex Pharmaceuticals, Inc. |
Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
|
EP2146689B1
(en)
|
2007-04-16 |
2020-08-12 |
Corium, Inc. |
Solvent-cast microneedle arrays containing active
|
US8911749B2
(en)
|
2007-04-16 |
2014-12-16 |
Corium International, Inc. |
Vaccine delivery via microneedle arrays
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
SI2152250T1
(sl)
|
2007-05-07 |
2020-06-30 |
Evonik Operations Gmbh |
Trdne dozirne oblike, ki vsebujejo enterično oplaščenje s pospešenim sproščanjem zdravila
|
BRPI0814542A2
(pt)
*
|
2007-07-12 |
2014-09-30 |
Tragara Pharmaceuticals Inc |
Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
|
CA2699151A1
(en)
*
|
2007-09-11 |
2009-03-19 |
Activx Biosciences, Inc. |
Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
|
CA2699152C
(en)
|
2007-09-12 |
2015-11-24 |
Activx Biosciences, Inc. |
Spirocyclic aminoquinolones as gsk-3 inhibitors
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
CN102014638A
(zh)
*
|
2007-10-12 |
2011-04-13 |
武田制药北美公司 |
与食物摄入无关的治疗胃肠病症的方法
|
US8802156B2
(en)
|
2007-11-14 |
2014-08-12 |
Laboratorios Farmacéuticos Rovi, S.A. |
Pharmaceutical forms for the release of active compounds
|
SG186008A1
(en)
|
2007-11-21 |
2012-12-28 |
Pharmaxis Ltd |
Haloallylamine inhibitors of ssao/vap-1 and uses therefor
|
WO2009111611A2
(en)
*
|
2008-03-05 |
2009-09-11 |
Proteotech Inc. |
Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
|
DK2268623T3
(da)
*
|
2008-03-17 |
2015-06-29 |
Ambit Biosciences Corp |
Quinazolinderivater som raf-kinasemodulatorer og fremgangsmåder til anvendelse deraf
|
US20120034156A1
(en)
*
|
2010-08-03 |
2012-02-09 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Artificial cells
|
CN101658533A
(zh)
*
|
2008-08-29 |
2010-03-03 |
首都医科大学宣武医院 |
抗肿瘤药物的干细胞递送
|
MX2011003595A
(es)
|
2008-10-03 |
2011-07-28 |
Falk Pharma Gmbh |
Composiciones y metodos para el tratamiento de enfermedades intestinales con mesalamina granulada.
|
LT2364360T
(lt)
|
2008-11-13 |
2017-08-10 |
Nogra Pharma Limited |
Priešprasmės kompozicijos ir jų gavimo bei panaudojimo būdai
|
AU2010207740B2
(en)
*
|
2009-01-26 |
2016-06-16 |
Nitec Pharma Ag |
Delayed-release glucocorticoid treatment of asthma
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
NZ582836A
(en)
*
|
2009-01-30 |
2011-06-30 |
Nitec Pharma Ag |
Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
SI2401267T1
(sl)
|
2009-02-27 |
2014-05-30 |
Ambit Biosciences Corporation |
Derivati kinazolina, ki modulirajo JAK-kinazo, in njihova uporaba v postopkih
|
WO2010101967A2
(en)
|
2009-03-04 |
2010-09-10 |
Idenix Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole hcv polymerase inhibitors
|
MX2011009414A
(es)
*
|
2009-03-11 |
2011-10-19 |
Kyorin Seiyaku Kk |
7-cicloalquiloaminoquinolonas como inhibidores de gsk-3.
|
MX2011009413A
(es)
|
2009-03-11 |
2011-10-21 |
Ambit Biosciences Corp |
Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
US8461158B2
(en)
|
2009-03-27 |
2013-06-11 |
Pathway Therapeutics Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
SG10201505313RA
(en)
|
2009-04-22 |
2015-08-28 |
Axikin Pharmaceuticals Inc |
2,5-Disubstituted Arylsulfonamide CCR3 Antagonists
|
NZ595838A
(en)
|
2009-04-22 |
2014-03-28 |
Axikin Pharmaceuticals Inc |
Arylsulfonamide ccr3 antagonists
|
CA2758985A1
(en)
|
2009-04-22 |
2010-10-28 |
Axikin Pharmaceuticals, Inc. |
2,5-disubstituted arylsulfonamide ccr3 antagonists
|
WO2011003870A2
(en)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
|
TW201105662A
(en)
|
2009-07-07 |
2011-02-16 |
Pathway Therapeutics Ltd |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
CA2767168C
(en)
|
2009-07-08 |
2019-04-09 |
Hope Medical Enterprises, Inc. D.B.A. Hope Pharmaceuticals |
Sodium thiosulfate-containing pharmaceutical compositions
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
JP2013501068A
(ja)
|
2009-08-05 |
2013-01-10 |
アイディニックス ファーマシューティカルズ インコーポレイテッド |
大環状セリンプロテアーゼ阻害剤
|
EP2467137A1
(en)
|
2009-08-19 |
2012-06-27 |
Ambit Biosciences Corporation |
Biaryl compounds and methods of use thereof
|
WO2011056566A2
(en)
|
2009-10-26 |
2011-05-12 |
Sunesis Pharmaceuticals, Inc. |
Compounds and methods for treatment of cancer
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
EP2499282B1
(en)
|
2009-11-09 |
2015-04-22 |
NeuroGenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
MX2012006240A
(es)
|
2009-12-02 |
2012-10-03 |
Aptalis Pharma Ltd |
Microcapsulas de fexofenadina y composiciones que contienen las mismas.
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
NZ600608A
(en)
|
2009-12-18 |
2015-01-30 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
EP2515654A4
(en)
*
|
2009-12-23 |
2013-04-24 |
Map Pharmaceuticals Inc |
NEW ERGOLINANALOGA
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
SI2538930T1
(sl)
*
|
2010-02-23 |
2016-10-28 |
Da Volterra |
Formulacije za oralno dostavo adsorbentov v črevesju
|
HUE025699T2
(en)
|
2010-03-02 |
2016-04-28 |
Axikin Pharmaceuticals Inc |
Isotopically enriched arylsulfonamide derivatives as CCR3 antagonists
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
CN102892754A
(zh)
|
2010-03-17 |
2013-01-23 |
埃克希金医药品有限公司 |
芳基磺酰胺ccr3拮抗剂
|
EP2566501B1
(en)
|
2010-05-04 |
2019-03-13 |
Corium International, Inc. |
Method and device for transdermal delivery of parathyroid hormone using a microprojection array
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
WO2011153199A1
(en)
|
2010-06-01 |
2011-12-08 |
Biotheryx, Inc. |
Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
|
CA2801001A1
(en)
|
2010-06-01 |
2011-12-08 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
|
AU2011265047B2
(en)
|
2010-06-07 |
2014-10-23 |
Novomedix, Llc |
Furanyl compounds and the use thereof
|
MX347927B
(es)
|
2010-07-19 |
2017-05-19 |
Summa Health System |
Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
|
WO2012030924A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
US20130225578A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
WO2012030948A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Quinazoline compounds and methods of use thereof
|
US20130225615A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
US20130317045A1
(en)
|
2010-09-01 |
2013-11-28 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
WO2012030918A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
EP2663553B1
(en)
|
2010-09-01 |
2015-08-26 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
CA2809993A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
EP2611794A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
MX2013002383A
(es)
|
2010-09-01 |
2013-07-05 |
Ambit Biosciences Corp |
Sales bromhidrato de una pirazolilaminoquinazolina.
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
CA2814011A1
(en)
|
2010-10-11 |
2012-04-19 |
Axikin Pharmaceuticals, Inc. |
Salts of arylsulfonamide ccr3 antagonists
|
US20140079686A1
(en)
|
2010-12-06 |
2014-03-20 |
Shikha P. Barman |
Methods For Treating Baldness And Promoting Hair Growth
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
DK2668210T3
(da)
|
2011-01-26 |
2020-08-24 |
Celldex Therapeutics Inc |
Anti-kit antistoffer og anvendelser deraf
|
WO2012106299A1
(en)
|
2011-01-31 |
2012-08-09 |
Celgene Corporation |
Pharmaceutical compositions of cytidine analogs and methods of use thereof
|
AR085352A1
(es)
|
2011-02-10 |
2013-09-25 |
Idenix Pharmaceuticals Inc |
Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
|
WO2012135166A1
(en)
|
2011-03-28 |
2012-10-04 |
Pathway Therapeutics Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
SG193982A1
(en)
|
2011-03-28 |
2013-11-29 |
Mei Pharma Inc |
(alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
|
WO2012135175A1
(en)
|
2011-03-28 |
2012-10-04 |
Pathway Therapeutics Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
JP5813391B2
(ja)
*
|
2011-06-24 |
2015-11-17 |
日東電工株式会社 |
粒子製剤の製造方法
|
WO2012177962A1
(en)
|
2011-06-23 |
2012-12-27 |
Map Pharmaceuticals, Inc. |
Novel fluoroergoline analogs
|
US10154964B2
(en)
|
2011-09-07 |
2018-12-18 |
Cosmo Technologies Limited |
Controlled release and taste masking oral pharmaceutical composition
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
TWI650321B
(zh)
|
2011-10-14 |
2019-02-11 |
美商安比特生物科學公司 |
雜環化合物及其使用方法
|
EP2599477A1
(en)
|
2011-11-30 |
2013-06-05 |
Lunamed AG |
4-Phenylbutyric acid sustained release formulation
|
WO2013095707A1
(en)
|
2011-12-19 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Novel iso-ergoline derivatives
|
EP2793583A4
(en)
|
2011-12-21 |
2015-08-12 |
Map Pharmaceuticals Inc |
NOVEL NEUROMODULATORY CONNECTIONS
|
JP2012107058A
(ja)
*
|
2012-02-27 |
2012-06-07 |
Warner Chilcott Co Llc |
複数のコーティングを有する医薬剤形
|
WO2013130600A1
(en)
|
2012-02-29 |
2013-09-06 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
EP2822542A1
(en)
*
|
2012-03-07 |
2015-01-14 |
Santarus, Inc. |
Controlled-release solid dosage forms of mesalamine
|
KR20140138293A
(ko)
|
2012-03-16 |
2014-12-03 |
액시킨 파마수티컬스 인코포레이티드 |
3,5-다이아미노피라졸 키나아제 억제제
|
CN109172816A
(zh)
|
2012-03-29 |
2019-01-11 |
塞拉拜姆有限责任公司 |
在回肠和阑尾上有活性的胃肠位点特异性口服接种疫苗制剂
|
PT2844637T
(pt)
|
2012-05-02 |
2018-04-17 |
Boehringer Ingelheim Int |
Inibidores de 3-haloalilamina substituídos de ssao e as suas utilizações
|
CN103417380B
(zh)
*
|
2012-05-22 |
2016-01-06 |
正和制药股份有限公司 |
具有肠溶膜衣的硬胶囊
|
US9732038B2
(en)
|
2012-06-14 |
2017-08-15 |
Mayo Foundation For Medical Education And Research |
Pyrazole derivatives as inhibitors of STAT3
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
CN116574185A
(zh)
|
2012-07-25 |
2023-08-11 |
塞尔德克斯医疗公司 |
抗kit抗体及其用途
|
US9074186B2
(en)
|
2012-08-15 |
2015-07-07 |
Boston Medical Center Corporation |
Production of red blood cells and platelets from stem cells
|
WO2014033077A1
(en)
|
2012-08-28 |
2014-03-06 |
Dsm Sinochem Pharmaceuticals Netherlands B.V. |
Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at| least one of them is in the form of mini-tablets
|
KR20150053906A
(ko)
|
2012-09-07 |
2015-05-19 |
액시킨 파마수티컬스 인코포레이티드 |
동위원소 농축 아릴설폰아미드 ccr3 길항제
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
WO2014074765A2
(en)
|
2012-11-08 |
2014-05-15 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
DK2925718T3
(da)
|
2012-11-30 |
2018-10-22 |
Novomedix Llc |
Substituerede biarylsulfonamider og anvendelse deraf
|
US9169214B2
(en)
|
2012-12-21 |
2015-10-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
|
CA2896188C
(en)
|
2012-12-21 |
2021-02-23 |
Corium International, Inc. |
Microarray for delivery of therapeutic agent and methods of use
|
US8895743B2
(en)
|
2012-12-21 |
2014-11-25 |
Map Pharmaceuticals, Inc. |
Methysergide derivatives
|
WO2014110305A1
(en)
|
2013-01-11 |
2014-07-17 |
Mayo Foundation For Medical Education And Research |
Vitamins c and k for treating polycystic diseases
|
ES2921481T3
(es)
|
2013-03-12 |
2022-08-26 |
Corium Inc |
Aplicadores para microproyecciones
|
AU2014239883B2
(en)
|
2013-03-14 |
2019-01-17 |
Therabiome, Llc |
Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
|
AU2014233695A1
(en)
|
2013-03-15 |
2015-10-01 |
Corium International, Inc. |
Microarray for delivery of therapeutic agent and methods of use
|
BR112015022432B1
(pt)
|
2013-03-15 |
2022-02-15 |
Corium, Inc |
Arranjo de microestrutura, método para fabricação do mesmo e formulação líquida para formar microestruturas de dissolução
|
AU2014237279B2
(en)
|
2013-03-15 |
2018-11-22 |
Corium Pharma Solutions, Inc. |
Microarray with polymer-free microstructures, methods of making, and methods of use
|
WO2014144973A1
(en)
|
2013-03-15 |
2014-09-18 |
Corium International, Inc. |
Microarray for delivery of therapeutic agent, methods of use, and methods of making
|
WO2014152450A1
(en)
|
2013-03-15 |
2014-09-25 |
Warner Chilcott Company, Llc |
Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
|
EP2968751B1
(en)
|
2013-03-15 |
2022-11-30 |
Corium, Inc. |
Multiple impact microprojection applicators
|
SG11201509982UA
(da)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
RU2016111675A
(ru)
|
2013-08-30 |
2017-10-04 |
Эмбит Байосайенсиз Корпорейшн |
Соединения биарилацетамида и способы их применения
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
US20160229866A1
(en)
|
2013-09-20 |
2016-08-11 |
Idenix Pharmaceuticals Inc. |
Hepatitis c virus inhibitors
|
JP6870988B2
(ja)
|
2014-02-24 |
2021-05-19 |
セルジーン コーポレイション |
神経細胞増幅及び中枢神経系障害治療のためのセレブロンの活性化因子の使用方法
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
WO2015134560A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
PT3119762T
(pt)
|
2014-03-20 |
2021-08-31 |
Capella Therapeutics Inc |
Derivados de benzimidazole como inibidores de tirosina quinase erbb para o tratamento do cancro
|
CA2943231C
(en)
|
2014-03-20 |
2023-10-24 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
|
MX2016014731A
(es)
|
2014-05-12 |
2017-05-04 |
Conatus Pharmaceuticals Inc |
Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
|
RS61678B1
(sr)
|
2014-05-28 |
2021-05-31 |
Agenus Inc |
Anti-gitr antitela i postupci za njihovu primenu
|
US9527815B2
(en)
|
2014-06-18 |
2016-12-27 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
WO2016025129A1
(en)
|
2014-08-14 |
2016-02-18 |
Alhamadsheh Mamoun M |
Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
|
EP3193828B8
(en)
|
2014-08-29 |
2023-04-05 |
Corium Pharma Solutions, Inc. |
Microstructure array for delivery of active agents
|
WO2016036866A1
(en)
|
2014-09-04 |
2016-03-10 |
Corium International, Inc. |
Microstructure array, methods of making, and methods of use
|
AU2015314830B2
(en)
|
2014-09-12 |
2021-01-07 |
Tobira Therapeutics, Inc. |
Cenicriviroc combination therapy for the treatment of fibrosis
|
EP3209658A1
(en)
|
2014-10-24 |
2017-08-30 |
Biogen MA Inc. |
Diterpenoid derivatives and methods of use thereof
|
PT3333191T
(pt)
|
2014-12-11 |
2020-12-15 |
Pf Medicament |
Anticorpos anti-c10orf54 e suas utilizações
|
EP3789039A1
(en)
|
2014-12-22 |
2021-03-10 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
MY191736A
(en)
|
2014-12-23 |
2022-07-13 |
Axikin Pharmaceuticals Inc |
3,5-diaminopyrazole kinase inhibitors
|
CA2974113A1
(en)
|
2015-01-20 |
2016-07-28 |
Xoc Pharmaceuticals, Inc. |
Isoergoline compounds and uses thereof
|
CN107428745A
(zh)
|
2015-01-20 |
2017-12-01 |
Xoc制药股份有限公司 |
麦角灵化合物及其用途
|
US20180002328A1
(en)
|
2015-01-28 |
2018-01-04 |
Jn Therapeutics |
Substituted imidazo[1, 2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
|
BR112017015880A2
(pt)
|
2015-03-03 |
2018-07-31 |
Kymab Ltd |
anticorpos, usos e métodos
|
JP6900323B2
(ja)
|
2015-05-29 |
2021-07-07 |
アジェナス インコーポレイテッド |
抗ctla−4抗体およびその使用方法
|
MX2017017015A
(es)
|
2015-06-23 |
2018-02-26 |
Neurocrine Biosciences Inc |
Inhibidores de transportador de monoamina vesicular tipo 2 (vmat2) para tratar enfermedades o trastornos neurologicos.
|
US10857093B2
(en)
|
2015-06-29 |
2020-12-08 |
Corium, Inc. |
Microarray for delivery of therapeutic agent, methods of use, and methods of making
|
EP3344656A1
(en)
|
2015-09-01 |
2018-07-11 |
Agenus Inc. |
Anti-pd-1 antibodies and methods of use thereof
|
KR20180075591A
(ko)
|
2015-10-30 |
2018-07-04 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
발베나진 염 및 그의 다형체
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
HUE059065T2
(hu)
|
2015-12-23 |
2022-10-28 |
Neurocrine Biosciences Inc |
Szintetikus eljárás (S)-(2R,3R,11BR)-3-izobutil-9,10-dimetoxi-2,3,4,6,7,11B-hexahidro-1H-pirido [2,1-A]izokinolin-2-il-2-amino-3-metilbutanoát-di(4-metilbenzolszulfonát) elõállítására
|
WO2017117478A1
(en)
|
2015-12-31 |
2017-07-06 |
Conatus Pharmaceuticals Inc. |
Methods of using caspase inhibitors in treatment of liver disease
|
WO2017120415A1
(en)
|
2016-01-08 |
2017-07-13 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
CN113662941A
(zh)
|
2016-01-08 |
2021-11-19 |
细胞基因公司 |
抗增殖化合物以及其药物组合物和用途
|
WO2017151836A1
(en)
|
2016-03-04 |
2017-09-08 |
East Carolina University |
J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
|
EP3426352A4
(en)
|
2016-03-08 |
2019-11-13 |
Los Gatos Pharmaceuticals, Inc. |
CAMPTOTHECIN DERIVATIVES AND USES THEREOF
|
US10064855B2
(en)
|
2016-03-08 |
2018-09-04 |
Los Gatos Pharmaceuticals, Inc. |
Composite nanoparticles and uses thereof
|
EP3429573A4
(en)
|
2016-03-17 |
2019-10-30 |
Thiogenesis Therapeutics, Inc. |
COMPOSITIONS FOR THE CONTROLLED RELEASE OF CYSTEAMINE AND FOR SYSTEMIC TREATMENT OF CYSTEAMIN SENSITIVE DISEASES
|
CN108884019A
(zh)
|
2016-04-11 |
2018-11-23 |
克雷西奥生物科技有限公司 |
氘代氯胺酮衍生物
|
WO2017180794A1
(en)
|
2016-04-13 |
2017-10-19 |
Skyline Antiinfectives, Inc. |
Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
|
EP3445340A1
(en)
*
|
2016-04-19 |
2019-02-27 |
Ferring B.V. |
Oral pharmaceutical compositions of mesalazine
|
WO2017184563A1
(en)
|
2016-04-19 |
2017-10-26 |
Ferring B.V. |
Oral pharmaceutical compositions of nicotinamide
|
EP4190357A1
(en)
|
2016-05-13 |
2023-06-07 |
Institut Pasteur |
Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
SG11201810023QA
(en)
|
2016-05-27 |
2018-12-28 |
Agenus Inc |
Anti-tim-3 antibodies and methods of use thereof
|
CN109689685A
(zh)
|
2016-07-08 |
2019-04-26 |
斯塔滕生物技术有限公司 |
抗apoc3抗体及其使用方法
|
US10919904B2
(en)
|
2016-08-17 |
2021-02-16 |
North Carolina State University |
Northern-southern route to synthesis of bacteriochlorins
|
KR20190058550A
(ko)
|
2016-09-19 |
2019-05-29 |
메이 파마, 아이엔씨. |
병용 요법
|
CA3037380A1
(en)
|
2016-10-11 |
2018-04-19 |
Agenus Inc. |
Anti-lag-3 antibodies and methods of use thereof
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
KR102539159B1
(ko)
|
2016-11-07 |
2023-06-02 |
주식회사 뉴라클사이언스 |
서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
|
US10106521B2
(en)
|
2016-11-09 |
2018-10-23 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
US10988442B2
(en)
|
2016-11-09 |
2021-04-27 |
Novomedix, Llc |
Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use
|
US10836774B2
(en)
|
2016-11-30 |
2020-11-17 |
North Carolina State University |
Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
|
WO2018102455A1
(en)
|
2016-12-01 |
2018-06-07 |
Ignyta, Inc. |
Methods for the treatment of cancer
|
JP2020500875A
(ja)
|
2016-12-02 |
2020-01-16 |
ニューロクライン バイオサイエンシーズ,インコーポレイテッド |
統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
|
KR102504605B1
(ko)
|
2016-12-07 |
2023-03-02 |
아게누스 인코포레이티드 |
항-ctla-4 항체 및 이의 사용 방법
|
CA3046082A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Antibodies and methods of use thereof
|
CA3051832A1
(en)
|
2017-01-27 |
2018-08-02 |
Neurocrine Bioscienes, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
CN110662548A
(zh)
|
2017-02-17 |
2020-01-07 |
卡姆瑞斯国际公司 |
通用抗毒液素
|
WO2018151815A1
(en)
|
2017-02-17 |
2018-08-23 |
Eidos Therapeutics, Inc. |
Processes for preparing ag-10, its intermediates, and salts thereof
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
US20200330590A1
(en)
|
2017-03-27 |
2020-10-22 |
Celgene Corporation |
Methods and compositions for reduction of immunogenicity
|
BR112019017241A2
(pt)
|
2017-04-13 |
2020-04-14 |
Agenus Inc |
anticorpos anti-cd137 e métodos de uso dos mesmos
|
MA50958A
(fr)
|
2017-04-21 |
2020-10-14 |
Staten Biotechnology B V |
Anticorps anti-apoc3 et leurs méthodes d'utilisation
|
US20200179352A1
(en)
|
2017-04-26 |
2020-06-11 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
CA3062061A1
(en)
|
2017-05-01 |
2018-11-08 |
Agenus Inc. |
Anti-tigit antibodies and methods of use thereof
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
KR20200005576A
(ko)
*
|
2017-05-17 |
2020-01-15 |
컨플루언스 파마슈티컬스, 엘엘씨 |
호모타우린 및 이의 염의 제형
|
JP2020522504A
(ja)
|
2017-06-01 |
2020-07-30 |
エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc |
多環式化合物およびそれらの用途
|
BR112019027729A2
(pt)
|
2017-06-27 |
2020-08-18 |
Neuracle Science Co., Ltd |
anticorpos anti-fam19a5 e seus usos
|
JP7012384B2
(ja)
|
2017-06-27 |
2022-02-14 |
ニューラクル サイエンス カンパニー リミテッド |
癌治療のための抗fam19a5抗体の用途
|
EP3645039A4
(en)
|
2017-06-27 |
2021-05-05 |
Neuracle Science Co., Ltd |
USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS
|
CN110972463B
(zh)
|
2017-06-27 |
2024-05-28 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5抗体在治疗青光眼中的用途
|
AU2018324070B2
(en)
|
2017-09-01 |
2023-05-18 |
East Carolina University |
Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response
|
US11612576B2
(en)
|
2017-09-20 |
2023-03-28 |
Thiogenesis Therapeutics, Inc. |
Methods for the treatment of cysteamine sensitive disorders
|
ES2938609T3
(es)
|
2017-09-20 |
2023-04-13 |
Tillotts Pharma Ag |
Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión
|
TW201919622A
(zh)
|
2017-09-21 |
2019-06-01 |
美商紐羅克里生物科學有限公司 |
高劑量戊苯那嗪(valbenazine)調配物及組合物、方法以及相關套組
|
US10993941B2
(en)
|
2017-10-10 |
2021-05-04 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
EA202090932A1
(ru)
|
2017-10-10 |
2021-05-20 |
Нейрокрин Байосайенсиз, Инк |
Способы введения некоторых vmat2-ингибиторов
|
WO2019087115A1
(en)
|
2017-10-31 |
2019-05-09 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
EP3501503A1
(en)
|
2017-12-22 |
2019-06-26 |
Cosmo Technologies Ltd. |
Solid delivery composition
|
WO2019139871A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
TWI823890B
(zh)
|
2018-01-10 |
2023-12-01 |
美商克拉治療有限責任公司 |
包含苯基磺醯胺之醫藥組合物及其治療應用
|
CN112218632A
(zh)
|
2018-03-23 |
2021-01-12 |
文涵治疗有限公司 |
用ag10治疗ttr淀粉样变性的方法
|
AU2019259798A1
(en)
|
2018-04-24 |
2020-11-12 |
Neuracle Science Co., Ltd. |
Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain
|
AU2019265888A1
(en)
|
2018-05-10 |
2020-11-26 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
SG11202011544UA
(en)
|
2018-06-14 |
2020-12-30 |
Neurocrine Biosciences Inc |
Vmat2 inhibitor compounds, compositions, and methods relating thereto
|
US11447497B2
(en)
|
2018-06-29 |
2022-09-20 |
Histogen, Inc. |
(S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
EP3824287A1
(en)
|
2018-07-20 |
2021-05-26 |
Pierre Fabre Médicament |
Receptor for vista
|
JOP20200336A1
(ar)
|
2018-08-15 |
2020-12-22 |
Neurocrine Biosciences Inc |
طرق إعطاء مثبطات vmat2 معينة
|
EA202190561A1
(ru)
|
2018-08-17 |
2021-05-26 |
Эйдос Терапьютикс, Инк. |
Препараты ag10
|
JP2022504287A
(ja)
|
2018-10-03 |
2022-01-13 |
スターテン・バイオテクノロジー・ベー・フェー |
ヒト及びカニクイザルapoc3に特異的な抗体、並びにその使用の方法
|
CN113365650A
(zh)
|
2018-11-16 |
2021-09-07 |
新免疫技术有限公司 |
用il-7蛋白和免疫检查点抑制剂的组合治疗肿瘤的方法
|
KR20200071198A
(ko)
|
2018-12-10 |
2020-06-19 |
네오이뮨텍, 인코퍼레이티드 |
Nrf2 발현 조절 기반 T 세포 항암면역치료법
|
IT201800011120A1
(it)
|
2018-12-14 |
2020-06-14 |
Dpl Pharma S P A |
Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati
|
WO2020132071A1
(en)
|
2018-12-19 |
2020-06-25 |
Shy Therapeutics. Llc |
Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
|
US11447468B2
(en)
|
2019-02-06 |
2022-09-20 |
Dice Alpha, Inc. |
IL-17 ligands and uses thereof
|
CA3130303A1
(en)
|
2019-02-26 |
2020-09-03 |
Rgenix, Inc. |
High-affinity anti-mertk antibodies and uses thereof
|
TW202100506A
(zh)
|
2019-03-07 |
2021-01-01 |
美商柯納特斯製藥公司 |
半胱天冬酶(caspase)抑制劑及其使用方法
|
WO2020236818A1
(en)
|
2019-05-20 |
2020-11-26 |
Nirvana Sciences Inc. |
Narrow emission dyes, compositions comprising same, and methods for making and using same
|
US20220274922A1
(en)
|
2019-07-11 |
2022-09-01 |
Cura Therapeutics, Llc |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
AU2020310190A1
(en)
|
2019-07-11 |
2022-02-24 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
AU2020335928A1
(en)
|
2019-08-30 |
2022-02-17 |
Agenus Inc. |
Anti-CD96 antibodies and methods of use thereof
|
WO2021055376A1
(en)
|
2019-09-16 |
2021-03-25 |
Dice Alpha, Inc. |
Il-17a modulators and uses thereof
|
WO2021146191A1
(en)
|
2020-01-13 |
2021-07-22 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
|
EP4093751A1
(en)
|
2020-01-22 |
2022-11-30 |
Outpace Bio, Inc. |
Chimeric polypeptides
|
JP2023512657A
(ja)
|
2020-02-05 |
2023-03-28 |
ワシントン・ユニバーシティ |
Il-7タンパク質とcar保有免疫細胞の組み合わせで固形腫瘍を治療する方法
|
US11529331B2
(en)
|
2020-05-29 |
2022-12-20 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
WO2022061348A1
(en)
|
2020-09-16 |
2022-03-24 |
Biotheryx, Inc. |
Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
TW202231269A
(zh)
|
2020-10-23 |
2022-08-16 |
美商拜歐斯瑞克斯公司 |
Kras蛋白降解劑、其醫藥組合物及其治療應用
|
KR20230104176A
(ko)
|
2020-11-02 |
2023-07-07 |
네오이뮨텍, 인코퍼레이티드 |
코로나바이러스의 치료를 위한 인터류킨-7의 용도
|
AU2021376396A1
(en)
|
2020-11-05 |
2023-06-08 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
|
TW202237580A
(zh)
|
2020-12-14 |
2022-10-01 |
美商拜歐斯瑞克斯公司 |
Pde4降解劑、醫藥組合物及治療應用
|
WO2022164997A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
US20220280585A1
(en)
*
|
2021-03-05 |
2022-09-08 |
Poopermints, LLC |
Pharmaceutical composition containing champignon extract and peppermint and methods of use thereof
|
JP2024510196A
(ja)
|
2021-03-10 |
2024-03-06 |
ダイス・モレキュールズ・エスブイ・インコーポレイテッド |
アルファvベータ6およびアルファvベータ1インテグリン阻害剤およびその使用
|
EP4326721A1
(en)
|
2021-04-22 |
2024-02-28 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
WO2022251533A1
(en)
|
2021-05-27 |
2022-12-01 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
EP4347826A1
(en)
|
2021-06-02 |
2024-04-10 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
EP4355776A1
(en)
|
2021-06-14 |
2024-04-24 |
Argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
AU2022292649A1
(en)
|
2021-06-16 |
2024-01-04 |
Biotheryx, Inc. |
Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
WO2022266249A1
(en)
|
2021-06-16 |
2022-12-22 |
Biotheryx, Inc. |
Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
WO2023055045A1
(ko)
|
2021-09-29 |
2023-04-06 |
주식회사 엔바이오스 |
코일드 코일 융합 단백질
|
WO2023081923A1
(en)
|
2021-11-08 |
2023-05-11 |
Frequency Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
WO2023130081A1
(en)
|
2021-12-30 |
2023-07-06 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and vegf antagonist
|
US11981694B2
(en)
|
2022-01-03 |
2024-05-14 |
Lilac Therapeutics, Inc. |
Acyclic thiol prodrugs
|
US11932665B2
(en)
|
2022-01-03 |
2024-03-19 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
WO2023192904A1
(en)
|
2022-03-30 |
2023-10-05 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
US20230331693A1
(en)
|
2022-04-14 |
2023-10-19 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the novel compounds
|
WO2023215781A1
(en)
|
2022-05-05 |
2023-11-09 |
Biomarin Pharmaceutical Inc. |
Method of treating duchenne muscular dystrophy
|
WO2023220640A1
(en)
|
2022-05-10 |
2023-11-16 |
Biotheryx, Inc. |
Cdk protein degraders, pharmaceutical compositions, and therapeutic applications
|
WO2023225665A1
(en)
|
2022-05-19 |
2023-11-23 |
Lyell Immunopharma, Inc. |
Polynucleotides targeting nr4a3 and uses thereof
|
US20240158370A1
(en)
|
2022-09-09 |
2024-05-16 |
Innovo Therapeutics, Inc. |
CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
|
US20240131005A1
(en)
|
2022-09-30 |
2024-04-25 |
Boulder Bioscience Llc |
Compositions and methods for treating non-hemorrhagic closed head injury
|
WO2024086852A1
(en)
|
2022-10-21 |
2024-04-25 |
Diagonal Therapeutics Inc. |
Heteromeric agonistic antibodies to il-18 receptor
|
US20240174695A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Bicyclic Heteroaryl Compounds
|
US20240174673A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridine Compounds
|
US20240174672A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridone Compounds
|
WO2024102722A1
(en)
|
2022-11-07 |
2024-05-16 |
Neoimmunetech, Inc. |
Methods of treating a tumor with an unmethylated mgmt promoter
|